Clare Arnott
The George Institute for Global Health (Sydney, Australia) · The George Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Clare Arnott as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:46 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05345327 · SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 DiabetesThe George Institute · recruiting · Type 2 Diabetes · study chair
- Ph4NCT05129722 · Polydiuretic Therapy for HFpEF, a Randomised Controlled TrialThe George Institute · terminated · Heart Failure With Preserved Ejection Fraction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:46 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.Eur Heart J · 2021105 citationsRCR 6.7
- Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China.Circulation · 202094 citationsRCR 4.5
- Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.Diabetologia · 202176 citationsRCR 4.6
- Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial.Am J Clin Nutr · 202155 citationsRCR 4.1
- Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.Diabetes Care · 202254 citationsRCR 3.8
- Electronic versus dictated hospital discharge summaries: a randomized controlled trial.J Gen Intern Med · 200949 citationsRCR 1.8
- Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.Clin J Am Soc Nephrol · 202246 citationsRCR 3.6
- Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study.Clin Ther · 201940 citationsRCR 1.7
- The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.Diabetes Obes Metab · 202040 citationsRCR 1.9
- Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.Diabetes Obes Metab · 202236 citationsRCR 2.6